Analysis of sera from Phase 1/2 booster study demonstrates 54- and 47-fold increases in geometric mean neutralizing antibody titers against the Omicron variant at Day 29 for ARCT-154 (5 mcg) and ...
(RTTNews) - Valneva SE (VALN) said its adjuvanted COVID-19 vaccine candidate, VLA2001, met both co-primary endpoints in phase 3, Cov-Compare trial. VLA2001 showed superiority against AstraZeneca's ...
In a recent study posted to the medRxiv* preprint server, researchers evaluated the cross-reactivity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant-triggered ...
A research team collaborating across the University of Texas Medical Branch-Galveston, Pfizer Vaccine Research, and BioNTech SE recently conducted a study on the neutralization capacity of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results